Phase I single ascending dose and multiple ascending dose study of 2R,6R-hydroxynorketamine
Ended Awarded Last action
- Contract number
- 75N95018F00002
- Awardee
-
Duke University UEI TP7EK8DZV6N5
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,115,865
Award facts
- Opportunity
-
- NIHNINDS1501 Solicitation number
- Phase I Clinical Trials for Development of Neurotherapeutics Award Notice · Posted Jun 18, 2015
- Contract value 100% obligated
- $3,115,865.14 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Durham, NC 27705, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $120,756 | |
| Funding Only Action | $1,193,931 | |
| Supplemental Agreement for work within scope | $272,423 | |
| Supplemental Agreement for work within scope | $8,388 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $26,620 | |
| Original award | $1,493,747 |
About this award
Duke University has been awarded a cost-no-fee delivery order against the Phase I Clinical Trials for Development of Neurotherapeutics IDIQ by the National Institutes of Health National Center for Advancing Translational Sciences. The $3,115,865.14 delivery order is for a Phase I single ascending dose and multiple ascending dose study of 2R,6R-hydroxynorketamine to be completed by May 31, 2024. As the prime contractor, Duke University will conduct the clinical trial in Durham, North Carolina to support the National Institutes of Health's mission of turning discovery into health through clinical research on neurotherapeutics. No set-aside designation was used for this award.
Quick answers
Who was awarded contract 75N95018F00002?
75N95018F00002 was awarded to Duke University by National Institute on Drug Abuse (National Institutes of Health) on September 6, 2018.
How much is contract 75N95018F00002 worth?
The government has obligated $3,115,865 on 75N95018F00002.
Which agency awarded contract 75N95018F00002?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95018F00002, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95018F00002 an order under another contract?
Yes. 75N95018F00002 is a delivery order under HHSN271201600004I, an indefinite delivery contract, on Phase I Clinical Trials for Development of Neurotherapeutics.
Was contract 75N95018F00002 competed?
The extent of competition for 75N95018F00002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award